Who
Andrew R. Boll
President and CFO
Company insider
Files Form 4 as: President and CFO, Harrow.
In numbers
- Trades disclosed
- 60
- Buys
- 3
- Sells
- 0
- Bought
- $313K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 28 Feb 2012
- Last trade
- 14 May 2026
- Last filed
- 15 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 May 2026filed 15 May 2026 | HROW HarrowPharmaceuticals | SEC FORM 4 Bought | $105K3,500 at $29.90 | filing |
| 14 May 2026filed 15 May 2026 | HROW HarrowPharmaceuticals | SEC FORM 4 Bought | $105K3,500 at $29.90 | filing |
| 12 Dec 2025filed 16 Dec 2025 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —60,000 at $0.00 | filing |
| 12 Dec 2025filed 16 Dec 2025 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | $237K60,000 at $3.95 | filing |
| 12 Dec 2025filed 16 Dec 2025 | HROW HarrowPharmaceuticals | SEC FORM 4 Code F | $1.3M26,665 at $47.06 | filing |
| 1 Jul 2025filed 1 Jul 2025 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —405,750 at $0.00 | filing |
| 7 Apr 2025filed 7 Apr 2025 | HROW HarrowPharmaceuticals | SEC FORM 4 Code F | $3.2M136,745 at $23.09 | filing |
| 3 Apr 2025filed 7 Apr 2025 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —346,500 at $0.00 | filing |
| 3 Apr 2025filed 7 Apr 2025 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | —346,500 at $0.00 | filing |
| 20 Feb 2024filed 21 Feb 2024 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —45,000 at $0.00 | filing |
| 20 Feb 2024filed 21 Feb 2024 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | $480K45,000 at $10.67 | filing |
| 20 Feb 2024filed 21 Feb 2024 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | $197K18,480 at $10.67 | filing |
| 7 Feb 2024filed 8 Feb 2024 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —7,400 at $0.00 | filing |
| 7 Feb 2024filed 8 Feb 2024 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | $57K7,400 at $7.71 | filing |
| 18 Jul 2023filed 20 Jul 2023 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —346,500 at $0.00 | filing |
| 18 Jul 2023filed 20 Jul 2023 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | —346,500 | filing |
| 18 Jul 2023filed 20 Jul 2023 | HROW HarrowPharmaceuticals | SEC FORM 4 Code F | $2.5M136,350 at $18.23 | filing |
| 3 Apr 2023filed 4 Apr 2023 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —346,500 at $0.00 | filing |
| 31 Mar 2023filed 4 Apr 2023 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —90,000 at $0.00 | filing |
| 31 Mar 2023filed 4 Apr 2023 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | $540K90,000 at $6.00 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)HROW · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Andrew R. Boll; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.